Ligand Pharmaceuticals (LGND) Segment Reporting, Other Segment Item, Amount — Quarterly & Annual

Screener

Segment Reporting, Other Segment Item, Amount at other companies

ConocoPhillipsCOP

$7.45B+42.3%

PRA GroupPRAA

$35.48M-6.5%

Matthews InternationalMATW

-$15.63M-883%

Collegium Pharmaceutical, Inc.COLL

$25.48M+4,316%

Radiant LogisticsRLGT

-$271K-113%

Microbot MedicalMBOT

$557K+7.3%

Segments

By segment

Development and Licensing of Biopharmaceutical Assets-$1.13M-105%

Other financials

Income statement

Revenue$63.7M+33.7%

Operating income$8.6M+1.7%

Net income$48.5M+901%

EPS (diluted)$2.22+825%

Balance sheet

Cash & equivalents$1.0B+1,388%

Total debt$1.1B+19,605%

Total equity$967.5M+16.9%

Total assets$2.2B+130%

Cash flow

Operating cash flow$24.0M+52.0%

CapEx$26.0K-87.9%

Free cash flow$24.0M+53.9%

Valuation

Market cap$6.02B+119%

Enterprise value$6.14B+129%

P/E30.5×—

P/S20.7×+6.1×

Profitability

Gross margin91.9%—

Operating margin32.6%+24.0pp

Net margin67.9%+49.4pp

FCF margin45.2%+16.7pp

Returns & leverage

Return on equity22%+16.9pp

Debt / equity1.2×+1.2×

Current ratio31.2×+25.7×